Institution
Hospital Punta Pacifica
Healthcare•Panama City, Panama•
About: Hospital Punta Pacifica is a healthcare organization based out in Panama City, Panama. It is known for research contribution in the topics: Latin Americans & Health care. The organization has 30 authors who have published 26 publications receiving 247 citations.
Papers
More filters
••
Valparaiso University1, Heidelberg University2, Danube University Krems3, University of São Paulo4, Clínica Alemana5, University of Chile6, Universidad del Desarrollo7, American Heart Association8, Texas Tech University Health Sciences Center at El Paso9, Federal University of São Paulo10, Stroke Association11, Federal University of Bahia12, Pan American Health Organization13, World Health Organization14, National University of Colombia15, Rafael Advanced Defense Systems16, Universidad Autónoma de Nuevo León17, Hospital Punta Pacifica18, Universidad Nacional de Asunción19, Universidad San Francisco de Quito20, The George Institute for Global Health21, Heart and Stroke Foundation of Canada22, Auckland University of Technology23
TL;DR: The meeting culminated with the adoption of the special Gramado Declaration, signed by all Ministerial officials who attended the meeting and an opportunity now exists to translate this Declaration into an action plan to reduce the burden of stroke.
Abstract: Summary The large and increasing burden of stroke in Latin American countries, and the need to meet the UN and WHO requirements for reducing the burden from non-communicable disorders (including stroke), brought together stroke experts and representatives of the Ministries of Health of 13 Latin American countries for the 1st Latin American Stroke Ministerial meeting in Gramado, Brazil, to discuss the problem and identify ways of cooperating to reduce the burden of stroke in the region. Discussions were focused on the regional and country-specific activities associated with stroke prevention and treatment, including public stroke awareness, prevention strategies, delivery and organisation of care, clinical practice gaps, and unmet needs. The meeting culminated with the adoption of the special Gramado Declaration, signed by all Ministerial officials who attended the meeting. With agreed priorities for stroke prevention, treatment, and research, an opportunity now exists to translate this Declaration into an action plan to reduce the burden of stroke.
105 citations
••
Reacct Collaborative1, Alexandra M Zaborowski, Ahmed Abdile2, Michel Adamina3 +218 more•Institutions (76)
TL;DR: Early-onset colorectal cancer (younger than 50 years) appears to represent a unique disease process with different clinical, pathological, and molecular characteristics compared with late-onset colon cancer, and sensitivity to conventional neoadjuvant and adjuvant therapy regimens appear to be unknown as mentioned in this paper.
Abstract: Importance The incidence of early-onset colorectal cancer (younger than 50 years) is rising globally, the reasons for which are unclear. It appears to represent a unique disease process with different clinical, pathological, and molecular characteristics compared with late-onset colorectal cancer. Data on oncological outcomes are limited, and sensitivity to conventional neoadjuvant and adjuvant therapy regimens appear to be unknown. The purpose of this review is to summarize the available literature on early-onset colorectal cancer. Observations Within the next decade, it is estimated that 1 in 10 colon cancers and 1 in 4 rectal cancers will be diagnosed in adults younger than 50 years. Potential risk factors include a Westernized diet, obesity, antibiotic usage, and alterations in the gut microbiome. Although genetic predisposition plays a role, most cases are sporadic. The full spectrum of germline and somatic sequence variations implicated remains unknown. Younger patients typically present with descending colonic or rectal cancer, advanced disease stage, and unfavorable histopathological features. Despite being more likely to receive neoadjuvant and adjuvant therapy, patients with early-onset disease demonstrate comparable oncological outcomes with their older counterparts. Conclusions and Relevance The clinicopathological features, underlying molecular profiles, and drivers of early-onset colorectal cancer differ from those of late-onset disease. Standardized, age-specific preventive, screening, diagnostic, and therapeutic strategies are required to optimize outcomes.
76 citations
••
University of Buenos Aires1, Universidad del Desarrollo2, University of Texas Health Science Center at Houston3, Monterrey Institute of Technology and Higher Education4, Universidad Mayor5, University of Chile6, Hospital Universitario La Paz7, University of Cartagena8, Hospital Punta Pacifica9, Central University of Venezuela10, Universidad de Especialidades Espíritu Santo11, Texas A&M Health Science Center College of Medicine12, University of Florida13
TL;DR: The evidence does not support the use of routine bronchoscopy guidance or laryngeal masks during the procedure, and proper prior training is as important or even a more significant factor in reducing complications than the technique used.
75 citations
••
TL;DR: UC‐MSC administration in children with ASD was determined to be safe, and some signals of efficacy were observed in a small group of children, although possible links between inflammation levels and ASD symptoms should be further investigated.
Abstract: Individuals with autism spectrum disorder (ASD) suffer from developmental disabilities that impact communication, behavior, and social interaction. Immune dysregulation and inflammation have been linked to children with ASD, the latter manifesting in serum levels of macrophage-derived chemokine (MDC) and thymus, and activation-regulated chemokine (TARC). Mesenchymal stem cells derived from umbilical cord tissue (UC-MSCs) have immune-modulatory and anti-inflammatory properties, and have been safely used to treat a variety of conditions. This study investigated the safety and efficacy of UC-MSCs administered to children diagnosed with ASD. Efficacy was evaluated with the Autism Treatment Evaluation Checklist (ATEC) and the Childhood Autism Rating Scale (CARS), and with measurements of MDC and TARC serum levels. Twenty subjects received a dose of 36 million intravenous UC-MSCs every 12 weeks (four times over a 9-month period), and were followed up at 3 and 12 months after treatment completion. Adverse events related to treatment were mild or moderate and short in duration. The CARS and ATEC scores of eight subjects decreased over the course of treatment, placing them in a lower ASD symptom category when compared with baseline. MDC and TARC inflammatory cytokine levels also decreased for five of these eight subjects. The mean MDC, TARC, ATEC, and CARS values attained their lowest levels 3 months after the last administration. UC-MSC administration in children with ASD was therefore determined to be safe. Although some signals of efficacy were observed in a small group of children, possible links between inflammation levels and ASD symptoms should be further investigated. Stem Cells Translational Medicine 2019;8:1008-1016.
48 citations
••
University of Buenos Aires1, University of Texas MD Anderson Cancer Center2, Monterrey Institute of Technology and Higher Education3, Universidad Mayor4, University of Chile5, Hospital Universitario La Paz6, University of Cartagena7, Hospital Punta Pacifica8, Central University of Venezuela9, Universidad de Especialidades Espíritu Santo10, Texas A&M Health Science Center College of Medicine11, Universidad del Desarrollo12, University of Florida13
TL;DR: La traqueostomia percutanea se asocia a menor riesgo de infecciones en comparacion with the traquestomia quirurgica, y el entrenamiento adecuado previo es tanto o mas importante que the tecnica utilizada para disminuir las complicaciones.
29 citations
Authors
Showing all 30 results
Name | H-index | Papers | Citations |
---|---|---|---|
Fernando Diaz Subía | 2 | 2 | 10 |
Antonio Cachafeiro-Vilar | 2 | 5 | 15 |
G. Castillo Abrego | 2 | 2 | 71 |
Scarlett Sinisterra | 1 | 1 | 1 |
Charles McKeever | 1 | 2 | 21 |
Alcibiades Solis | 1 | 1 | 1 |
Jorge Sinclair | 1 | 1 | 53 |
Nelson Novarro | 1 | 1 | 34 |
Isabel Blanco | 1 | 1 | 7 |
José Ricardo Ruíz Obaldía | 1 | 1 | 5 |
Ingrid Persky | 1 | 1 | 1 |
Tania T. Herrera | 1 | 3 | 6 |
H Rodriguez-Zentner | 1 | 1 | 3 |
M Cukier | 1 | 1 | 3 |
Leticia Ruiz | 1 | 2 | 21 |